Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24788127 | 0.96 | GPR119 (0.32) | GPR119CYP4F2CYP4A11 | |
| SCHEMBL24762272 | 0.95 | GPR119 (0.34) | GPR119CYP4F2CYP4A11 | |
| SCHEMBL23314147 | 0.84 | — | — | |
| SCHEMBL20128802 | 0.81 | HRH3 (0.34) | — | |
| SCHEMBL24654251 | 0.75 | CHRM1 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL21025696 | 0.74 | HRH3 (0.32) | — | |
| SCHEMBL21471849 | 0.73 | HRH3 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL23350029 | 0.72 | HRH3 (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL24654228 | 0.70 | HRH3 (0.30) | — | |
| SCHEMBL20317416 | 0.68 | HRH3 (0.31) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | GPR119 1215/4885CYP4F2 3279/4885CYP4A11 3593/4885 |
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | PTK2, CTTN, CRBN | GPR119 3505/4885CYP4F2 4649/4885CYP4A11 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.